What question did this study set out to answer?

To review the pharmacological mechanism, preclinical efficacy, and clinical utility of retigabine as a novel potassium channel-opening antiepileptic drug.

December 1, 2010Clinical Pharmacology Advances and ApplicationsOpen Access

Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine

View Full Paper

Ask AI

Bookmark

Why the study?

What is the role and potential of retigabine as an add-on treatment for pharmacoresistant epilepsy?

Population

Patients with pharmacoresistant epilepsy

Design

Review

Authors

MTMaurizio TaglialatelaElectrophysiology BBarreseUniversity of Naples Federico II MMiceliBambino Gesù Children's Hospital

Discussion

Member takes

Implication

May support retigabine as add-on in pharmacoresistant epilepsy; leaves open confirmation in randomized trials.

Key Points

To review the pharmacological mechanism, preclinical efficacy, and clinical utility of retigabine as a novel potassium channel-opening antiepileptic drug.
Reviewed the physiological role of voltage-gated Kv7 potassium channels in regulating intrinsic and neurotransmitter-induced neuronal excitability.
Summarized findings from preclinical in vitro and in vivo models evaluating the anticonvulsant properties of retigabine.
Analyzed clinical trial developments for retigabine as an adjunctive treatment for pharmacoresistant epilepsy, comparing its advantages and disadvantages to existing antiepileptic drugs.
Retigabine reduces intrinsic and network-level neuronal hyperexcitability by selectively activating voltage-gated potassium channels of the Kv7 subfamily.
Preclinical and clinical evidence confirms retigabine provides robust anticonvulsant effects as an add-on treatment for patients with drug-resistant epilepsy.

Structured PICO

What is the role and potential of retigabine as an add-on treatment for pharmacoresistant epilepsy?

Population

Patients with pharmacoresistant epilepsy

Intervention

Retigabine (neuronal potassium channel opener targeting Kv7 subfamily)

Outcome

Seizure control

Retigabine offers a novel mechanism of action (Kv7 channel opening) for the approximately 30% of epilepsy patients who do not achieve seizure control with current drugs.

Cite This Study

Taglialatela et al. (2010) studied this question.

synapsesocial.com/papers/6a7cd8227396d1123d91adc8 https://doi.org/10.2147/cpaa.s15369

View Full Paper

Ask AI

Bookmark

Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider